Synonyms: GPRC5D, RAIG4
Anti-GPRC5D is a specific antibody against G protein-coupled receptor C5 family member D (GPRC5D).
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | GPR | Others |
|---|---|---|---|
| AZD1981 | 1 | ||
| NF-56-EJ40 | 0 | ||
| ML401 | 0 | ||
| PH-064 | 0 | ||
| NE 52-QQ57 | 2 | IL-1β,TNF-α,PGE2 | |
| NIBR189 | 0 | ||
| JMS-17-2 | 2 | ||
| OC000459 | 0 | ||
| Kisspeptin-10 (human) | 0 | ||
| CLP-3094 | 0 | AR |
| Description |
Anti-GPRC5D is a specific antibody against G protein-coupled receptor C5 family member D (GPRC5D).
|
|---|
| CAS No. | 2226212-40-2 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT07474961 | NOT_YET_RECRUITING | Drug: teclistamab OR talquetamab OR elranatamab OR linvoselt | Waldenstrom Macroglobulinaemia; Multiple Myeloma | Anne Louise Tølbøll Sørensen | 2027-03 | PHASE4 |
| NCT07455851 | RECRUITING | Drug: Linvoseltamab|Drug: REGN17372+Linvoseltamab | Relapsed Refractory Multiple Myeloma (RRMM) | Regeneron Pharmaceuticals | 2026-03-26 | PHASE1; PHASE2 |
| NCT07649525 | RECRUITING | Drug: Daratumumab|Drug: Lenalidomide|Drug: Dexamethasone|Dru | Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) | University of Leeds | 2026-07 | PHASE3 |
| NCT07740486 | NOT_YET_RECRUITING | Drug: Teclistamab|Drug: Talquetamab|Drug: Daratumumab (Subcu | Multiple Myeloma (MM) | Polish Myeloma Consortium | 2026-09 | PHASE3 |
| NCT06630806 | RECRUITING | Drug: SAR446523 | Plasma Cell Myeloma Refractory | Sanofi | 2024-10-30 | PHASE1 |
| NCT05552222 | RECRUITING | Drug: Teclistamab|Drug: Daratumumab|Drug: Lenalidomide|Drug: | Multiple Myeloma | Janssen Research & Development, LLC | 2022-10-25 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-03-16)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.